Further transformation of low-grade gliomas with an IDH mutation to secondary GBM requires more genetic alterations, such as the amplification of epidermal growth factor receptor (EGFR) and lost expression of the phosphatase and tensin homolog (PTEN) [20]. The gene discussed is IDH2; the disease is central nervous system cancer.